Biohaven is a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological diseases, including rare disorders. Our product candidates are small molecules based on two distinct mechanistic platforms—calcitonin gene-related peptide, or CGRP, receptor antagonists and glutamate modulators—which we believe have the potential to significantly alter existing treatment approaches across a diverse set of neurological indications with high unmet need in both large markets and orphan indications.

Stock Information

View Stock Information

Corporate Governance

View Our Board of Directors, Committees, and Governance Documents.

Read More

Contact Us

Access Our Investor Relations contact information to get in touch.

Read More

Email Alerts

Receive SEC Filings, Events, News Releases and Stock Price Alerts.